Calidi Biotherapeutics Statistics
Total Valuation
CLDI has a market cap or net worth of $2.47 million. The enterprise value is -$494,379.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDI has 11.05 million shares outstanding. The number of shares has increased by 544.98% in one year.
| Current Share Class | 10.90M |
| Shares Outstanding | 11.05M |
| Shares Change (YoY) | +544.98% |
| Shares Change (QoQ) | +45.14% |
| Owned by Insiders (%) | 2.83% |
| Owned by Institutions (%) | 4.71% |
| Float | 10.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.68.
| Current Ratio | 1.59 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -65.93 |
Financial Efficiency
Return on equity (ROE) is -700.65% and return on invested capital (ROIC) is -165.07%.
| Return on Equity (ROE) | -700.65% |
| Return on Assets (ROA) | -109.81% |
| Return on Invested Capital (ROIC) | -165.07% |
| Return on Capital Employed (ROCE) | -411.21% |
| Weighted Average Cost of Capital (WACC) | 10.76% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$882,034 |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLDI has paid $15,000 in taxes.
| Income Tax | 15,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.09% in the last 52 weeks. The beta is 1.42, so CLDI's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | -96.09% |
| 50-Day Moving Average | 0.41 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 31.86 |
| Average Volume (20 Days) | 9,535,878 |
Short Selling Information
The latest short interest is 275,084, so 2.49% of the outstanding shares have been sold short.
| Short Interest | 275,084 |
| Short Previous Month | 186,549 |
| Short % of Shares Out | 2.49% |
| Short % of Float | 2.60% |
| Short Ratio (days to cover) | 0.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.24M |
| Pretax Income | -20.05M |
| Net Income | -25.58M |
| EBITDA | -18.59M |
| EBIT | -20.24M |
| Earnings Per Share (EPS) | -$5.95 |
Full Income StatementBalance Sheet
The company has $5.60 million in cash and $2.56 million in debt, giving a net cash position of $3.04 million or $0.27 per share.
| Cash & Cash Equivalents | 5.60M |
| Total Debt | 2.56M |
| Net Cash | 3.04M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 3.76M |
| Book Value Per Share | 0.51 |
| Working Capital | 2.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.29 million and capital expenditures -$120,000, giving a free cash flow of -$21.41 million.
| Operating Cash Flow | -21.29M |
| Capital Expenditures | -120,000 |
| Depreciation & Amortization | 1.65M |
| Net Borrowing | -2.49M |
| Free Cash Flow | -21.41M |
| FCF Per Share | -$1.94 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |